We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · December 15, 2020

Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer

The Oncologist

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Oncologist
Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair‐Deficient Prostate Cancer
Oncologist 2020 Nov 20;[EPub Ahead of Print], LA Sena, J Fountain, P Isaacsson Velho, SJ Lim, H Wang, E Nizialek, N Rathi, R Nussenzveig, BL Maughan, MG Velez, R Ashkar, AC Larson, CC Pritchard, N Adra, AH Bryce, N Agarwal, DM Pardoll, JR Eshleman, TL Lotan, ES Antonarakis

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading